Blood markers to predict poor blood flow after emergency artery opening in heart attack
Studies blood markers that may predict poor blood flow after emergency heart attack treatment.
Plain-language title generated from the registry record
Registry title: Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients
Key facts
- Where
- Sohag, EgyptSee the site
Where in Egypt
- Sohag UniversitySohag, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sohag University
- Trial code
- NCT07890168
- Record updated
- 22 October 2026
- Original description
This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), with the goal of improving early risk stratification and clinical decision-making.Read full original descriptionShow less
Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients; A Prospective Cohort Study
This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), with the goal of improving early risk stratification and clinical decision-making.
Inclusion: Age ≥18 years old; Both sexes; Diagnosis of ST-segment elevation myocardial infarction (STEMI) according to current ESC/ACC guidelines; Presentation within 12 hours of symptom onset; Undergoing primary percutaneous coronary intervention (PCI) as the reperfusion strategy.
Exclusion: Previous coronary artery bypass graft surgery (CABG); Current use of chronic corticosteroid or immunosuppressive therapy; Active infection or sepsis; Chronic inflammatory or autoimmune diseases; Hematological disorders; Active malignancy; Severe liver disease; End-stage renal disease requires dialysis.